These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 29628176)

  • 21. Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.
    Crandon JL; Luyt CE; Aubry A; Chastre J; Nicolau DP
    J Antimicrob Chemother; 2016 Sep; 71(9):2534-7. PubMed ID: 27272723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doripenem vs meropenem against Pseudomonas and Acinetobacter.
    Goyal K; Gautam V; Ray P
    Indian J Med Microbiol; 2012; 30(3):350-1. PubMed ID: 22885206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of doripenem against extended-spectrum beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates.
    Betriu C; Gómez M; López-Fabal F; Culebras E; Rodríguez-Avial I; Picazo JJ
    Eur J Clin Microbiol Infect Dis; 2010 Sep; 29(9):1179-81. PubMed ID: 20521156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A comparison of susceptibility of Pseudomonas aeruginosa clinical isolates to carbapenem antibiotics in our hospital].
    Kakeya H; Yamada K; Nakaie K; Takizawa E; Okada Y; Fujita A; Nakamura Y; Abe J; Hirose A; Kaneko Y; Hino M
    Jpn J Antibiot; 2014 Aug; 67(4):241-8. PubMed ID: 25420320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
    Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
    J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
    Kresken M; Körber-Irrgang B; Korte-Berwanger M; Pfennigwerth N; Gatermann SG; Seifert H;
    Int J Antimicrob Agents; 2020 Jun; 55(6):105959. PubMed ID: 32325200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA; Nicolau DP
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative In Vitro Efficacy of Doripenem and Imipenem Against Multi-Drug Resistant Pseudomonas aeruginosa.
    Wali N; Mirza IA
    J Coll Physicians Surg Pak; 2016 Apr; 26(4):297-301. PubMed ID: 27097701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Shall we report the carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii strains detected by BD Phoenix system?].
    Oğünç D; Ongüt G; Ozen NS; Baysan BO; Günseren F; Dağlar D; Demirbakan H; Gültekin M
    Mikrobiyol Bul; 2010 Apr; 44(2):197-202. PubMed ID: 20549953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial susceptibility testing of carbapenems: multicenter validity testing and accuracy levels of five antimicrobial test methods for detecting resistance in Enterobacteriaceae and Pseudomonas aeruginosa isolates.
    Steward CD; Mohammed JM; Swenson JM; Stocker SA; Williams PP; Gaynes RP; McGowan JE; Tenover FC
    J Clin Microbiol; 2003 Jan; 41(1):351-8. PubMed ID: 12517872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.
    Esterly JS; Qi C; Malczynski M; Scheetz MH
    Pharmacotherapy; 2010 Apr; 30(4):354-60. PubMed ID: 20334455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of carbapenem-resistant Pseudomonas aeruginosa strains in patients with ventilator-associated pneumonia in intensive care units.
    Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Bakšytė G; Macas A; Sakalauskas R
    Medicina (Kaunas); 2011; 47(12):652-6. PubMed ID: 22370463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between the consumption of meropenem or doripenem and meropenem susceptibility of Pseudomonas aeruginosa in a university hospital in Japan.
    Miyawaki K; Miwa Y; Seki M; Asari S; Tomono K; Kurokawa N
    Biol Pharm Bull; 2012; 35(6):946-9. PubMed ID: 22687536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
    Pillar CM; Torres MK; Brown NP; Shah D; Sahm DF
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4388-99. PubMed ID: 18779357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.
    Shigemi A; Matsumoto K; Yaji K; Shimodozono Y; Takeda Y; Miyanohara H; Kawamura H; Orita M; Tokuda K; Nishi J; Yamada K
    Int J Antimicrob Agents; 2009 Dec; 34(6):589-91. PubMed ID: 19748231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control.
    Brown SD; Traczewski MM
    J Antimicrob Chemother; 2005 Jun; 55(6):944-9. PubMed ID: 15872043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp.
    Mohanty S; Maurya V; Gaind R; Deb M
    J Infect Dev Ctries; 2013 Nov; 7(11):880-7. PubMed ID: 24240048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Susceptibility to chemotherapeutics and the occurrence of metallo-beta-lactamases in hospital Pseudomonas aeruginosa strains].
    Nowak P; Targosz A; Budak A; Oleksiak D; Geza G; Skałkowska M
    Med Dosw Mikrobiol; 2006; 58(3):231-7. PubMed ID: 17340998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.
    Kiratisin P; Chongthaleong A; Tan TY; Lagamayo E; Roberts S; Garcia J; Davies T
    Int J Antimicrob Agents; 2012 Apr; 39(4):311-6. PubMed ID: 22386743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative review of the carbapenems.
    Zhanel GG; Wiebe R; Dilay L; Thomson K; Rubinstein E; Hoban DJ; Noreddin AM; Karlowsky JA
    Drugs; 2007; 67(7):1027-52. PubMed ID: 17488146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.